Larazotide Acetate not checked

Interlude Biopharma Co.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Larazotide acetate will be taken as oral capsules TID, at the dose assigned per the study arm. Duration of treatment is 14 weeks.”In the company’s words, NCT07944625 on ClinicalTrials.gov
Tested for
Celiac Disease, Celiac Disease in Adolescents
Main trialPhase 3
“The goal of this clinical trial is to learn if larazotide acetate, which will be tested at two doses and compared to placebo, can help prevent signs and symptoms of celiac disease in patients with well-controlled celiac disease who are following a gluten-free diet. Both adults and children (ages 12 years and up) will be allowed to enroll in this study.”In the company’s words, NCT07944625 on ClinicalTrials.gov

Other drugs for Celiac Disease

All 6 drugs for Celiac Disease

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Aug 2028 Clinical Trial to Evaluate the Protective Effect of Larazotide Acetate in Individuals With Well-Controlled Celiac Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Larazotide Acetate

Following is part of Solo: you see every change to Larazotide Acetate the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in